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The Chance to Contribute to This Special Issue
I feel privileged to be asked to write something for this
collection of articles about aptamers. I was also flattered:
25 years is a long time to try to stay relevant! I decided to
break this short article into ‘‘First Moments,’’ the ‘‘NeXstar
Moment,’’ the ‘‘SomaLogic Moment,’’ and ‘‘Next
Moments.’’ By the section names alone, I hope the reader
will recognize a life lived with intense focus, the short-
sightedness of seeing the world through my own eyes, but
also a life lived reading the literature broadly. Without
concern, I did not cite many papers in this article because
most are old but well known; however, I am happy to
provide references to anyone who asks for them (email at
lgold@somalogic.com).
The First Moments
Craig Tuerk, a remarkable PhD student in Molecular,
Cellular, and Developmental Biology at the University of
Colorado in Boulder (and still a remarkable person, cur-
rently a Professor of Biology at Morehead State Univer-
sity), was finishing his thesis on the translational regulation
of the DNA polymerase gene of the bacteriophage T4. The
‘‘operator’’ on that mRNA was a binding site for the
polymerase, which thus repressed its own translation when
the polymerase level was high enough. That RNA
sequence/structure overlapped the ribosome binding site,
and was the piece of RNA that Craig studied. A hairpin,
with an intramolecular loop of eight nucleotides, was
within the operator and the loop became the subject of
Craig’s deep mutagenesis, in which every possible loop
sequence (all 48 of them) was selected for binding to the
polymerase. Two sequences emerged (the wild-type and
the major variant, containing four nucleotide changes
within those eight loop nucleotides) and Craig and I shared
the most wonderful moment possible for scientists: we
imagined a future in which RNAs were ‘‘shapes, not tapes’’
or ‘‘strings, not things’’ and were useful in the same way
that monoclonal antibodies are useful. Craig named the
process ‘‘SELEX’’ (Systematic Evolution of Ligands by
EXponential enrichment) in his Science paper (Tuerk and
Gold 1990), while Andy Ellington and Jack Szostak named
the resulting molecules ‘‘aptamers’’ in their Nature paper
(Ellington and Szostak 1990). Both words have stuck—one
‘‘does SELEX’’ and ‘‘gets aptamers.’’
Neither Andy and Jack nor Craig and I were the first to
do in vitro mutagenesis on this scale. Arnold Oliphant and
Kevin Struhl had published a beautiful paper in 1989; they
synthesized double-stranded DNA with 25 base pairs of
fully random sequence (425 sequences) and selected those
sequences that bound to the yeast transcription factor
GCN4 (Oliphant and Struhl 1989). That paper did not
utilize ‘‘rounds’’ of amplification and selection as SELEX
does, but PCR made that addition to the Oliphant/Struhl
procedure sensible; Oliphant and Struhl merely made a lot
of double-stranded DNA and used affinity chromatography
(two ‘‘rounds’’ without amplification between the rounds)
to pull out the right sequences.
The major difference between working on double-
stranded and single-stranded oligonucleotides was huge,
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we thought. Helices (of RNA or DNA) do not have, usu-
ally, fascinating shapes, while single-strands, with some
intramolecular Watson–Crick helices and lots more, really
are (or so we thought) like the antigen-binding sites of
monoclonal antibodies. We saw single-stranded oligonu-
cleotides as globular molecules, much like proteins. (All of
the work in our lab for almost two decades prior to this
moment considered mRNA to have functional
intramolecular structures, so we were ‘‘ready’’ for our
discovery.) For several days in a row, Craig and I dreamed
about monoclonal antibodies made out of nucleic acids.
The first scientist Craig and I talked to outside of our lab
was Ed Brody (then in Paris), who did not dump on our
idea; in fact, in 1999, he became part of the NeXstar-So-
maLogic team. Craig and I talked to a lot of scientists in
Boulder and elsewhere as we were writing the paper, and
Ed was one who thought it was sensible and generaliz-
able—most of our friends told us (gently, usually) that we
were being silly, even though we all knew by then about
Tom Cech’s group I intron’s catalytic activity.
The last 25 years have made the idea of ‘‘antibodies’’
made from single-stranded oligonucleotides a reality.
Today, because of the 10,000 or so papers about natural and
synthetic and aptamers and SOMAmer reagents, and prob-
ably as many papers about ribozymes, riboswitches and
DNAzymes, it is easy to think that we thought about
oligonucleotides as shapes in the early 1990’s. In fact, we did
think of RNA as a shape if and only if onewas thinking about
5S RNA, rRNA, a group I intron, RNase P, or a tRNA—that
is, if one was thinking about molecules that were thought to
be outliers! Even today, text books written by professionals
show mRNA as a random coil—as though base-pairing was
not inevitable for single-stranded oligonucleotides—I have
often called this the ‘‘tyranny of Watson-Crickery.’’ The
wonderful thing that Craig and Andy made more likely was
the generalization that there were huge numbers of shape
possibilities in single-stranded oligonucleotides, and the
SELEX protocol was going to identify them.
The NeXstar Moment
We started NeXagen in 1992. NeXagen became NeXstar
when we merged with Vestar, and then, we sold the whole
thing to Gilead in mid-1999. During those 7 years, we did a
lot of development of methods to expand how we thought
about and performed SELEX. The major accomplishments
at NeXstar centered on Macugen, the first VEGF antagonist
approved for use in age-related macular degeneration
(AMD), and also on the PDGF aptamer antagonist that is
today undergoing clinical development by Ophthotech (this
compound is also for AMD, and appears—as Nebojsa
Janjic predicted almost 20 years ago—that inhibiting
PDGF and VEGF would synergize for diseases character-
ized by abundant and inappropriate angiogenesis, including
that process in the ‘‘wet’’ form of AMD). Nebojsa was the
major scientist at NeXstar (among many great scientists),
and both Macugen and the PDGF antagonist were identi-
fied in his group.
Bruce Eaton joined NeXagen early, and brought with
him methods for adding modifications to the five position
of the pyrimidines (see below), as well as doing early work
on the larger scale synthesis of aptamers. We also did cell-
SELEX, covalent-SELEX, photo-SELEX, and many other
additions to the breadth of SELEX; at one point, NeXstar
scientists published a remarkable selection aimed at a small
molecule—theophylline—which was nearly identical to
caffeine (which has a methyl instead of a hydrogen at a
single position); in that work, an RNA aptamer was iden-
tified that bound to theophylline about 104 more tightly
than to caffeine! At that time, antibodies raised against
theophylline were not nearly that selective against caffeine.
The SomaLogic Moment
When NeXstar was sold, many of the scientists moved
around the world into other biotech and pharma companies.
Nebojsa became the co-founder of an antibiotic discovery
and development company. Bruce started a company aimed
at using modified RNAs to do catalysis to identify orally
active drugs. Some NeXstar scientists were willing to join
me in 2000 to create SomaLogic, which was aimed at
developing diagnostics. Bruce and I were able separately to
negotiate the purchase of the required ‘‘NeXstar’’ IP from
Gilead (who was fair and helpful). Gilead knew what it
wanted from the NeXstar purchase and made it easy for
Bruce and me and, later, the founders of Archemix, to
continue our dreams.
SomaLogic was started around a simple idea that we had
said out loud at NeXstar in 1997. We knew that people
were going to crush genomics (which turned out to be right,
of course), and we knew that proteomics was going to be
far more difficult. We also believed (and I continue to
believe) that medical diagnostics was not as useful for
patients and healthcare as it had to be, and that personal-
ized medicine would depend on genomics and proteomics
(and other omics technologies). Before NeXstar was sold,
we thought we understood how to quantify thousands of
proteins using aptamers.
Because we were biochemists at heart (some of us had
become biochemists when fields like molecular biology did
not exist!), we fully understood that antibodies would
continue to be used for single analytes: ELISAs are a great
invention, and sandwich assays allow two elements of
specificity to generate enormous specificity! However, we
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also understood, through some modeling that Dom Zichi
did on the back of an envelope, that arrays of sandwich
ELISAs were going to reach quickly a content size that
would compromise signal-to-noise in the measurements.
So we set out to create arrays of aptamers that would allow
thousands of proteins to be measured at once, thus making
protein biomarker discovery as simple a process as mRNA,
microRNA, or SNP biomarker discovery is today.
To eliminate the intrinsic noise of sandwiches at high
density (which we have described in several publications),
we needed to select aptamers with two elements of speci-
ficity in a single molecule (a kind of ‘‘intramolecular
sandwich’’). We fiddled with coupling photo-crosslinking
along with high specificity binding, but moved rapidly (but
not as rapidly as we might have had I not been so stubborn)
toward a combination of kinetics with high specificity
binding. As we have written earlier, we were comforted by
the work of John Hopfield on ‘‘kinetic proof-reading’’ in
the mid-1970s, and understood from his work that kinetics
could be used to enhance specificity.
At that moment, more or less, we realized that the earlier
work at NeXstar by Bruce and his co-workers (on those
pyrimidine adducts that make oligonucleotides more
chemically diverse) was going to make the task of high
specificity-high affinity-slow off-rate binding a lot easier,
and we have extended Bruce’s work enormously. Medici-
nal chemists at SomaLogic, notably John Rohloff (with
Nebojsa, who has come back to his true home, and a team
of several additional chemists) have created a large set of
pyrimidine adducts, all sitting on the privileged five posi-
tion of Cytosine and Thymine; by privileged I mean only
that adducts at that position are accepted by many DNA
polymerases (both as templates for PCR and as triphos-
phates substrates)—the critical amplifications required for
rounds of SELEX could still be done.
During the last few years, the scientists at SomaLogic
have used thousands of proteins (mostly human, some
other mammals, and some bacterial) as SELEX targets,
using a collection of modified pyrimidines (with full sub-
stitution for any individual selection, to avoid a difficult
deconvolution). The four X-ray structures of complexes
between these novel aptamers and their target proteins
solved to date (three of these are published) support fully
that single-stranded oligonucleotides can be globular
molecules, much like proteins; the new ‘‘side chains’’
function in these new aptamers as do many different amino
acid side chains in proteins. What Bruce once called ‘‘side
chain envy’’ is no longer a problem; these new reagents
have the folding and target-contact opportunities of both
single-stranded oligonucleotides and proteins.
We have called these new reagents ‘‘SOMAmers’’ (Slow
Off-rate Modified Aptamers). We believe that additional
chemistries are more important to identifying great
aptamers than, for example, additional nucleotides (beyond
the canonical four) that can independently base pair with-
out confusing the canonical four. Additional base pairs are
interesting to me as a way of wondering about early evo-
lution. (My mentor Carl Woese did not have much time to
consider the question ‘‘why four nucleotides?’’—surely he
would have said something smart, since he always did
that.)
The primary use of the collection of SOMAmer reagents
has been to quantify proteins in biological matrices, using a
large (and expanding) multiplex platform called the
‘‘SOMAscan’’ assay. Biomarkers have been found
robustly, quickly, and reproducibly, using small amount of
precious samples, by SomaLogic and many academic and
pharma/biotech collaborators using this remarkable new
assay. Once found, protein biomarkers can be used in all
the common medical uses of protein detection (now done
largely with ELISAs or mass spectrometry), but with the
added capability of designing and implementing panels of
measurements aimed at particular medical problems. A
favorite paper in my life is the recent paper about Duch-
enne Muscular Dystrophy, published in PNAS with many
authors (Hathout et al. 2015), and driven largely by Pat
Furlong and Fintan Steele (an old friend who works at
SomaLogic). One of the joys of having the SOMAscan
assay running in our labs is that we get to collaborate with
wonderful people.
The Next Moments
I think of SOMAmer reagents (and, in fact, all aptamers) as
exact homologues of the antigen-binding domains of anti-
bodies, except that they are made of nucleic acids and thus
produced synthetically. As such it is trivial to functionalize
aptamers with anything that can be prepared as a phos-
phoramidite, and almost anything can be prepared that
way. This means that the future for applications of apta-
mers will be limited only by our imaginations, as is always
the case. Already aptamers have been used for proteomics,
cell sorting, pathology, affinity purification, and pharma-
ceuticals, and those are just the things that build on prior
work with antibodies.
I suspect that the many inventions to come will be based
on novel chemistries added to aptamers, as we have done,
but not limited to what we have done. Our focus has been
proteomics (for nearly two decades), but what if people
begin to address nanotechnology in all its (unexplored)
domains? Novel aptamers have beguiling qualities: chem-
ical synthesis, high affinity for one or more targets (large or
small), exquisite shape, acceptable resistance to things in
the environment, and uses we certainly have not said out
loud. I love the idea of material scientists imagining the
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properties they want in a small oligonucleotide, and further
imagining adding their stuff to those privileged five posi-
tions. Molecular origami will benefit from modified
pyrimidines and SELEX, as will nano-electrical devices—
SOMAmer reagents provide an opportunity to place in
space, in those beautiful globular entities, whatever one
imagines will be useful for any structural and functional
purposes (with binding being the earliest and easiest thing
to do). I look forward to the next 25 years for this field, and
expect to write another review on my 100th birthday.
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